Welcome to TDhelp.org
With our support groups you’re not alone
NOTD’s online support groups provide patients and caregivers with:
- A way to meet others with TD
- Share self-care tips
- Discuss treatments and TD triggers
- Get emotional support from others who understand the challenges TD presents
Available times:
Wednesday, 11 am – 12:30 pm ET
Thursday, 2 pm – 3:30 pm ET
Saturday, 11 am – 12:30 pm ET
Respiratory Dyskinesia Support Group
Alternating Tuesdays 11 am – 12:30 pm ET
Help us help those with Tardive Dyskinesia
KEEP OUR MISSION GOING - Contribute to our Crowdfunding Campaign
Whether you have TD, or a friend, patient or loved one does, just a small contribution will help NOTD make a big difference for those whose lives are impacted by this often debilitating, medication-induced disorder.
We are committed to this cause, but we can’t continue this mission without your support. Please give what you can. Every little bit helps. And rest assured that we will use your donation in the most responsible way to make the biggest impact we can for those with this often-disabling condition.
Your contribution will help us:
- Continue to provide online support groups
- Produce educational content such as patient guides and webinars
- Advocate on the Federal and State level for the estimated 750,000 people who have TD
- Host special in-person TD screening events
- Provide patients with convenient tools to manage their condition
Become a member of NOTD today
Whether you have TD, or a friend, patient or loved one does, just a small contribution will help NOTD make a big difference for those whose lives are impacted by this often debilitating, medication-induced disorder. Contribute just $5 per month and as a member you’ll receive special publications, the possibility to participate in advocacy activities, and more.
Your small monthly donation will help us:
- Provide online support groups
- Produce educational content such as patient guides and webinars
- Advocate on the Federal and State level for the estimated 750,000 people who have TD
- Host special in-person TD screening events
- Keep patients and healthcare practitioners updated with the latest TD news
Become a member today
TD News
Head-to-head comparison of Ingrezza and Austedo XR at inhibiting VMAT2
The results of a new study comparing Ingrezza and Austedo XR were presented this month at the American College of Neuropsychopharmacology 64th Annual Meeting. Results indicate that Ingrezza demonstrated significantly higher VMAT2 target occupancy and greater potency than Austedo XR.
You can read about the study on Neurocrine Biosciences’ newsroom here.
New medicine for schizophrenia with no TD? Cobenfy analyzed after first year of availability
Development of an antipsychotic that theoretically doesn’t carry any risk of tardive dyskinesia has long been a dream of those in the TD community. Just such a medicine, Cobenfy (xanomeline/trospium), was approved by the FDA to treat schizophrenia in late 2024.
While not actually labeled an antipsychotic, approval of Cobenfy was a major event in the psychiatric community because it promised to reduce psychotic symptoms without the numerous side effects that can be caused by antipsychotics that work primarily by blocking dopamine receptors.
The article, “From Approval to Practice: How Has Conbenfy’s New Mechanism of Action Impacted Psychiatry?,” published January 5, 2026 in Psychiatric Times, analyzes the effect the medicine caused, not only for patients, but for the psychiatric community as a whole in its first full year of availability.
It’s a worthwhile read for anyone who has TD, is at risk for it, or who prescribes antipsychotics.
New journal article compares VMAT2 inhibitors
Since 2017, healthcare practitioners have had two FDA-approved treatments for tardive dyskinesia (TD). But what they haven’t had is detailed information on the similarities and differences between these two medicines. With this detailed review, now professionals have more information to inform treatment of their patients.
Published on 10/22/25 in the peer-reviewed journal CNS Spectrums from Cambridge University Press, this article, “VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative review,” provides an in-depth comparison of the two medicines, valbenazine (Ingrezza) and deutetrabenazine (Austedo). While likely a bit technical for the average patient or loved one affected by TD, this is a first-of-its-kind look at the differences between these commonly prescribed medicines for TD.